How Many Aeterna Zentaris Inc. (NASDAQ:AEZS)’s Analysts Are Bullish?

June 18, 2018 - By Ash

Aeterna Zentaris Inc. (NASDAQ:AEZS) Ratings Coverage

Among 2 analysts covering Aeterna Zentaris (NASDAQ:AEZS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeterna Zentaris has $300 highest and $300 lowest target. $3’s average target is 40.19% above currents $2.14 stock price. Aeterna Zentaris had 3 analyst reports since March 29, 2018 according to SRatingsIntel. The stock of Aeterna Zentaris Inc. (NASDAQ:AEZS) earned “Buy” rating by H.C. Wainwright on Wednesday, May 9. The firm has “Buy” rating given on Thursday, March 29 by H.C. Wainwright. Below is a list of Aeterna Zentaris Inc. (NASDAQ:AEZS) latest ratings and price target changes.

15/06/2018 Broker: Maxim Group Rating: Buy Terminates
09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $3.0000 Maintain
29/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $3.0000 Maintain

The stock increased 1.42% or $0.03 during the last trading session, reaching $2.14. About 101,571 shares traded. Aeterna Zentaris Inc. (NASDAQ:AEZS) has risen 125.00% since June 18, 2017 and is uptrending. It has outperformed by 112.43% the S&P500.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company has market cap of $35.65 million. The companyÂ’s product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It has a 20.58 P/E ratio. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology.

More notable recent Aeterna Zentaris Inc. (NASDAQ:AEZS) news were published by: Benzinga.com which released: “58 Biggest Movers From Yesterday” on June 01, 2018, also Benzinga.com with their article: “37 Stocks Moving In Tuesday’s Mid-Day Session” published on May 29, 2018, Seekingalpha.com published: “Key events next week – healthcare” on June 15, 2018. More interesting news about Aeterna Zentaris Inc. (NASDAQ:AEZS) were released by: Benzinga.com and their article: “42 Biggest Movers From Yesterday” published on May 30, 2018 as well as Nasdaq.com‘s news article titled: “Aeterna Zentaris Appoints Olaf Althaus as General Manager and Managing Director of Aeterna Zentaris GmbH” with publication date: May 31, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: